1. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms
- Author
-
Tina Binderup, Andreas Kjaer, Birgitte Federspiel, Veronica Grøndahl, Seppo W. Langer, Linea Melchior, Ulrich Knigge, Kirstine Nielsen, and Pauline Knigge
- Subjects
0301 basic medicine ,Male ,p53 ,Cancer Research ,Survival ,Proliferation index ,Gastroenteropancreatic neuroendocrine neoplasms ,Prognostication ,Gastroenterology ,0302 clinical medicine ,Surgical oncology ,Receptors, Somatostatin ,Gastrointestinal Neoplasms ,Aged, 80 and over ,biology ,Chromogranin A ,Middle Aged ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Immunohistochemistry ,Oncology ,030220 oncology & carcinogenesis ,Female ,Research Article ,Adult ,endocrine system ,medicine.medical_specialty ,Carcinoma, Neuroendocrine/diagnosis ,Gastrointestinal Neoplasms/diagnosis ,lcsh:RC254-282 ,Neuroendocrine carcinomas ,03 medical and health sciences ,Young Adult ,Internal medicine ,Cell Line, Tumor ,mental disorders ,Genetics ,medicine ,Biomarkers, Tumor ,Humans ,Pancreatic Neoplasms/diagnosis ,Tumor Suppressor Protein p53/metabolism ,Aged ,Proportional Hazards Models ,Chromogranin A/metabolism ,business.industry ,Proportional hazards model ,NEC ,Somatostatin receptor 2a ,Carcinoma, Neuroendocrine ,Receptors, Somatostatin/metabolism ,Pancreatic Neoplasms ,030104 developmental biology ,biology.protein ,Synaptophysin ,Histopathology ,Tumor Suppressor Protein p53 ,Neoplasm Grading ,NET G3 ,business ,Immunostaining ,Follow-Up Studies - Abstract
Background High grade gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) with a Ki67 proliferation index > 20%, include well-differentiated tumours grade 3 (NET G3) and poorly differentiated (PD) neuroendocrine carcinomas (NEC). Abnormal p53-expression is a feature of PD tumours, while expression of chromogranin A (CgA) and somatostatin-receptor 2a (SSTR-2a) may be a feature of well-differentiated tumours. The aim of this study was to elucidate the expression and prognostic value of these three markers in 163 GEP-NEN patients with a Ki67-index > 20%. Method Clinical data, histopathology and overall survival were analysed according to Kaplan-Meier’s method and Cox regression. The expression of SSTR-2a, CgA and synaptophysin was analysed in tumour specimens by immunohistochemistry, and semi-quantitatively scored as negative ( 30%). P53 was defined as normal when scored as heterogeneously positive (1–30%), and abnormal when negative (0%) or strongly positive (> 30%). Results In multivariate analysis, better survival was observed among patients with heterogeneously positive p53 compared to strongly positive (p p = 0.002). Survival was significantly worse for negative CgA compared to heterogeneously positive CgA (p = 0.02). Strongly positive SSTR-2a expression was found in 26% of the 163 included patients. Well-differentiated morphology correlated with strong expression of SSTR-2a and CgA, and heterogeneously positive p53-staining, and was more frequent in pancreatic primaries. In pancreatic primaries, strongly positive SSTR-2a was associated with longer survival (univariate analysis, p = 0.02). A significantly lower Ki67 proliferation index was found in patients with a heterogeneously positive p53, a positive SSTR-2a and CgA expression. Conclusion Our results suggest that abnormal p53-expression is an independent negative prognostic marker in GEP-NEN with a Ki67-index > 20%. Patients with heterogeneously positive p53 had the best prognosis. SSTR-2a was a positive prognostic marker in pancreatic NEN. Negative CgA was associated with a significantly worse OS compared to heterogeneously positive CgA-expression in a multivariate sub-analysis. Lower Ki67 index correlated significantly with heterogeneously positive p53, positive SSTR-2a and CgA expression.
- Published
- 2020
- Full Text
- View/download PDF